【摘要】 目的 观察安心饮治疗气滞血瘀型微血管性心绞痛的临床疗效。方法 将2021年10月—2023年4月在中国中医科学院广安门医院济南医院（济南市中医医院）就诊的60例微血管性心绞痛气滞血瘀型患者随机分为对照组和试验组，各30例，对照组予西医常规治疗，试验组在对照组基础上予安心饮治疗，比较2组临床疗效及中医证候积分、一氧化氮（NO）、基质金属蛋白酶9(MMP-9)、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6的水平。结果 试验组临床疗效高于对照组（P<0.05）。治疗后，试验组中医证候总积分和5项单项积分低于对照组（P<0.05）；试验组NO水平高于对照组（P<0.05）,MMP-9、hs-CRP、TNF-α、IL-6水平低于对照组（P<0.05）。结论 安心饮可改善气滞血瘀型微血管性心绞痛患者的临床症状，调节血管内皮功能和减轻炎症反应，疗效较好。更多还原

【Abstract】 Objective To observe the clinical efficacy of Anxin drink in the treatment of microvascular angina(MVA) with qi stagnation and blood stasis syndrome. Methods A total of 60 patients with MVA of qi stagnation and blood stasis syndrome treated in Jinan Hospital, Guang’anmen Hospital, China Academy of Chinese Medical Sciences(Jinan Hospital of Traditional Chinese Medicine) from October 2021 to April 2023 were randomly divided into control group and experimental group, with 30 cases in each group. The control group received conventional Western medicine treatment, and the experimental group was treated with Anxin drink on the basis of the control group. The clinical efficacy, traditional Chinese medicine(TCM) syndrome scores, and levels of nitric oxide(NO), matrix metalloproteinase-9(MMP-9), high-sensitivity C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α), and interleukin-6(IL-6) were compared between the two groups. Results The clinical efficacy in the experimental group was higher than that in the control group(P<0.05). After treatment, the total TCM syndrome score and 5 individual item scores in the experimental group were lower than those in the control group(P<0.05), the NO level in the experimental group was higher than that in the control group(P<0.05), and the levels of MMP-9, hs-CRP, TNF-α and IL-6 were lower than those in the control group(P<0.05). Conclusion Anxin deink can improve clinical symptoms, regulate vascular endothelial function and reduce inflammatory response in patients with MVA of qi stagnation and blood stasis syndrome, with favorable efficacy.更多还原